• More then 18 years of age

• Diagnosis of RA for at least 6 months 

• Diagnosis of RA after the age of 16

• Must have a minimum of 6 swollen and 6 tender joints

• Body weight of at least 90 pounds

• Must have at least 1 bone erosion present on hand/wrist or foot (confirmed via x-ray at screening visit)

• Must be currently on one of the following medications without receiving adequate results:

               a. Methotrexate (MTX): weekly 15-25 mg oral or injected, for at                     least 12 weeks at the maximum tolerated dose prior to Day 1,                     with no change in route of administration in this time. A                             lower dose of ≥7.5 mg/week is acceptable if reduced for                               reasons of intolerance to MTX, e.g. nausea/vomiting, hepatic                     or hematologic toxicity, or per local requirement (there must                     be clear documentation in the medical record). Exception: A                       lower dose of 6 mg/week is allowed if the minimum locally                           approved or recommended dose is lower than 7.5 mg/week.
               b. Hydroxychloroquine up to 400 mg/day or chloroquine up to                       250 mg/day.
               c. Sulfasalazine up to 3000 mg/day.
               d. Leflunomide up to 20 mg/day. Note: concomitant use of                               leflunomide and methotrexate is not allowed, for safety                               reasons.
               e. Bucillamine up to 100 mg/day (or up to 300 mg/day if                                   permitted per local requirements).
               f. Iguratimod up to 50 mg/day.​